论文部分内容阅读
目的比较两药和三药联合化疗方案在Ⅲ期胃癌患者的疗效。方法Ⅲ期胃癌根治术后患者115例随机分为两组,分别实施两药联合(A组,61例)和三药联合(B组,54例)化疗,比较两组临床疗效和不良反应发生情况。结果 A组和B组3年生存率、中位无进展生存期和3年无复发率均无统计学差异(75.41%vs.74.07%、56.70个月vs.63.03个月和50.82%vs.51.85%)(P>0.05)。两组不良反应主要包括骨髓抑制、肝肾功能损伤、胃肠道反应和神经系统毒性等;A组Ⅱ-Ⅳ度贫血和乏力的发生率低于B组(14.75%vs.31.48%和27.87%vs.46.30%)(P<0.05)。结论与两药联合化疗相比,Ⅲ期胃癌根治术后三药联合化疗效果未明显改善,但不良反应有所增加。
Objective To compare the curative effect between two drugs and three drugs combined chemotherapy in patients with stage Ⅲ gastric cancer. Methods One hundred and fifteen patients with stage Ⅲ gastric cancer after radical operation were randomly divided into two groups. The two groups were combined with chemotherapy (group A, n = 61) and the combination of three drugs (group B, n = 54). The clinical efficacy and adverse reactions Happening. Results There was no significant difference in 3-year survival, median progression-free survival and 3-year recurrence between group A and group B (75.41% vs 74.07%, 56.70 months vs. 63.03 months and 50.82% vs.51.85 %) (P> 0.05). The two groups of adverse reactions mainly include myelosuppression, liver and renal dysfunction, gastrointestinal reaction and neurotoxicity. The incidence of grade Ⅱ-Ⅳ anemia and fatigue in group A was lower than that in group B (14.75% vs.31.48% and 27.87% vs.46.30%) (P <0.05). Conclusions Compared with the combination of the two drugs, the effect of the three drugs combined with chemotherapy after radical operation of stage Ⅲ gastric cancer has not obviously improved, but the side effects increased.